We are pleased to announce that Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, CYCCP) has completed a successful share purchase and change in control, marking a significant milestone for the company as it transitions leadership and charts a new path forward.

ARC Group assisted in facilitating the sale of 70% of Cyclacel’s issued and outstanding shares to Datuk Dr. Doris Wong Sing Ee for a total consideration of $6.3 million through the purchase of Series C and Series D Convertible Preferred Stock. As part of this transaction, Datuk Dr. Doris Wong Sing Ee was appointed Chief Executive Officer and Executive Director, alongside Kiu Cu Seng as Executive Director, Secretary, and Chief Financial Officer.

These leadership changes position Cyclacel for long-term growth as the company continues to advance its innovative oncology pipeline and deliver value to its stakeholders.

Nigel Wong, Vice President at ARC Group, commented, “This share transfer and change of control marks a transformative moment for Cyclacel, providing fresh leadership and a renewed strategic focus. We are honored to have supported both the incoming shareholder, management team, and Cyclacel during this pivotal period, and this transaction underscores ARC Group’s commitment to delivering strategic advisory services to innovative life sciences companies worldwide.”

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments targeting cell cycle and transcriptional regulation mechanisms. With a pipeline of promising drug candidates, Cyclacel aims to advance therapeutic options for oncology and hematology indications.

About ARC Group

ARC Group is a globally based investment bank and management consultancy firm, specializing in bridging Asia and the West. Our services encompass a full spectrum of financial solutions, including IPOs, M&A, financing, venture capital, and SPACs. ARC Group also includes an independent consulting division dedicated to addressing the unique challenges faced by companies operating across both Asian and Western markets. Headquartered in Hong Kong, with offices across Mainland China, the USA, Malaysia, Indonesia, Vietnam, India, Sweden, and the UAE, we are well-positioned to provide cross-border financial and advisory services.

Our commitment to anticipating market trends and delivering client-centered solutions has earned ARC Group the Frost & Sullivan 2024 Company of the Year Award in the Asian mid-market investment advisory sector.

For more information or any questions, please contact:

Nigel Wong
Vice President
nigel.wong@arc-group.com

For media inquiries, please contact:

Anna Sahlberg Carlsson
Marketing Manager
anna.sahlberg@arc-group.com